` BVAXF (Biovaxys Technology Corp) vs S&P 500 Comparison - Alpha Spread

B
BVAXF
vs
S&P 500

Over the past 12 months, BVAXF has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's +14% growth.

Stocks Performance
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Difference
www.alphaspread.com

Performance By Year
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Biovaxys Technology Corp vs Peers

S&P 500
BVAXF
AMGN
ARGX
ALNY
603259
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Biovaxys Technology Corp
Glance View

Market Cap
39.6m USD
Industry
N/A

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

BVAXF Intrinsic Value
0.002 USD
Overvaluation 99%
Intrinsic Value
Price
B
Back to Top